The document summarizes Singapore's legislative infrastructure and national coordination efforts related to combating counterfeit medical products. Key points include:
1) Singapore's Health Sciences Authority regulates medicines through various acts, but laws currently do not specifically address counterfeit medicines.
2) A new Health Products Act will consolidate laws, include specific definitions and prohibitions against counterfeit health products, and impose heavier penalties.
3) Singapore coordinates with other agencies but faces challenges from differing priorities and lack of medical expertise in other fields.
4) Reported counterfeit medicine cases primarily involve lifestyle drugs obtained through fringe markets rather than mainstream sources.
5. Legislative Infrastructure Importer ( foreign source ) Manufacturer ( local source ) Wholesaler Retailer User Model supply chain for medicines
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17. Cases of Counterfeit Medicines Number of Cases Investigated Note : Cases all involved ED drugs - Viagra, Cialis and/or Levitra Nil Imported 7 11 2005 Nil Imported 5 5 200 7 Nil Imported 4 8 2006 Vital Medicines Imported/ Domestic Confirmed Suspected Year
18. Cases of Counterfeit Medicines Number of Confirmed Cases 0 0 5 0 0 0 2007 2006 2 4 Detected at border checkpoints 0 0 Reported by affected manufacturer 1 2 Referrals from other agencies 1 1 Enforcement/Investigation work 0 0 Health professionals reports 0 0 Patients complaints 2005 Source of Case
19. Cases of Counterfeit Medicines Number of Cases Prosecuted Note : Offenders in all cases convicted – no cases pending 7 0 0 0 2005 5 0 0 0 200 7 4 0 0 0 2006 Informal Sector Retailer Importer/ Wholesaler Manufacturer Year
![Legislative Infrastructure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)